The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The human multidrug resistance ABC transporters provide a protective function in our body against a large number of toxic compounds. These proteins, residing in the plasma membrane, perform an active, ATP-dependent extrusion of such xenobiotics. However, the same proteins are also used by the tumor cells to fight various anticancer agents. ABCG2 is an important member of the multidrug resistance proteins, an 'ABC half transporter', which functions as a homodimer in the cell membrane. In this review, we provide a basic overview of ABCG2 function in physiology and drug metabolism, but concentrate on the discussion of mutations and polymorphisms discovered in this protein. Interestingly, a single nucleotide mutation, changing amino acid 482 from arginine to threonine or glycine in ABCG2, results in a major increase in the catalytic activity and a wider drug recognition by this protein. Still, this mutation proved to be an in vitro artifact, produced only in heavily drug-selected cell lines. In contrast, at least two, but possibly more polymorphic variants of ABCG2 were found to be present in large human populations with different ethnic background. However, currently available experimental data regarding the cellular expression, localization and function of these ABCG2 variants are strongly contradictory. Since, the proteins produced by these variant alleles may differently modulate cancer treatment, general drug absorption and toxicity, may represent risk factors in fetal toxicity, or alter the differentiation of stem cells, their exact characterization is a major challenge in this field.

Original languageEnglish
Pages (from-to)62-72
Number of pages11
JournalCancer Letters
Volume234
Issue number1
DOIs
Publication statusPublished - Mar 8 2006

Fingerprint

Toxicology
ATP-Binding Cassette Transporters
Neoplasms
Proteins
Mutation
Cell Membrane
Pharmaceutical Preparations
P-Glycoproteins
Therapeutics
Poisons
Multiple Drug Resistance
Xenobiotics
Threonine
Drug-Related Side Effects and Adverse Reactions
Antineoplastic Agents
Artifacts
Glycine
Arginine
Stem Cells
Nucleotides

Keywords

  • ABC transporter proteins
  • ABCG2
  • Cancer drug resistance
  • Multidrug transporter
  • Plymorphic variants
  • Xenobiotics resistance

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

@article{22df3f86e2c94499ac9150f5b4ef2961,
title = "The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology",
abstract = "The human multidrug resistance ABC transporters provide a protective function in our body against a large number of toxic compounds. These proteins, residing in the plasma membrane, perform an active, ATP-dependent extrusion of such xenobiotics. However, the same proteins are also used by the tumor cells to fight various anticancer agents. ABCG2 is an important member of the multidrug resistance proteins, an 'ABC half transporter', which functions as a homodimer in the cell membrane. In this review, we provide a basic overview of ABCG2 function in physiology and drug metabolism, but concentrate on the discussion of mutations and polymorphisms discovered in this protein. Interestingly, a single nucleotide mutation, changing amino acid 482 from arginine to threonine or glycine in ABCG2, results in a major increase in the catalytic activity and a wider drug recognition by this protein. Still, this mutation proved to be an in vitro artifact, produced only in heavily drug-selected cell lines. In contrast, at least two, but possibly more polymorphic variants of ABCG2 were found to be present in large human populations with different ethnic background. However, currently available experimental data regarding the cellular expression, localization and function of these ABCG2 variants are strongly contradictory. Since, the proteins produced by these variant alleles may differently modulate cancer treatment, general drug absorption and toxicity, may represent risk factors in fetal toxicity, or alter the differentiation of stem cells, their exact characterization is a major challenge in this field.",
keywords = "ABC transporter proteins, ABCG2, Cancer drug resistance, Multidrug transporter, Plymorphic variants, Xenobiotics resistance",
author = "Judit Cervenak and H. Andrikovics and C. {\"O}zvegy-Laczka and A. Tordai and K. N{\'e}met and A. V{\'a}radi and B. Sarkadi",
year = "2006",
month = "3",
day = "8",
doi = "10.1016/j.canlet.2005.01.061",
language = "English",
volume = "234",
pages = "62--72",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology

AU - Cervenak, Judit

AU - Andrikovics, H.

AU - Özvegy-Laczka, C.

AU - Tordai, A.

AU - Német, K.

AU - Váradi, A.

AU - Sarkadi, B.

PY - 2006/3/8

Y1 - 2006/3/8

N2 - The human multidrug resistance ABC transporters provide a protective function in our body against a large number of toxic compounds. These proteins, residing in the plasma membrane, perform an active, ATP-dependent extrusion of such xenobiotics. However, the same proteins are also used by the tumor cells to fight various anticancer agents. ABCG2 is an important member of the multidrug resistance proteins, an 'ABC half transporter', which functions as a homodimer in the cell membrane. In this review, we provide a basic overview of ABCG2 function in physiology and drug metabolism, but concentrate on the discussion of mutations and polymorphisms discovered in this protein. Interestingly, a single nucleotide mutation, changing amino acid 482 from arginine to threonine or glycine in ABCG2, results in a major increase in the catalytic activity and a wider drug recognition by this protein. Still, this mutation proved to be an in vitro artifact, produced only in heavily drug-selected cell lines. In contrast, at least two, but possibly more polymorphic variants of ABCG2 were found to be present in large human populations with different ethnic background. However, currently available experimental data regarding the cellular expression, localization and function of these ABCG2 variants are strongly contradictory. Since, the proteins produced by these variant alleles may differently modulate cancer treatment, general drug absorption and toxicity, may represent risk factors in fetal toxicity, or alter the differentiation of stem cells, their exact characterization is a major challenge in this field.

AB - The human multidrug resistance ABC transporters provide a protective function in our body against a large number of toxic compounds. These proteins, residing in the plasma membrane, perform an active, ATP-dependent extrusion of such xenobiotics. However, the same proteins are also used by the tumor cells to fight various anticancer agents. ABCG2 is an important member of the multidrug resistance proteins, an 'ABC half transporter', which functions as a homodimer in the cell membrane. In this review, we provide a basic overview of ABCG2 function in physiology and drug metabolism, but concentrate on the discussion of mutations and polymorphisms discovered in this protein. Interestingly, a single nucleotide mutation, changing amino acid 482 from arginine to threonine or glycine in ABCG2, results in a major increase in the catalytic activity and a wider drug recognition by this protein. Still, this mutation proved to be an in vitro artifact, produced only in heavily drug-selected cell lines. In contrast, at least two, but possibly more polymorphic variants of ABCG2 were found to be present in large human populations with different ethnic background. However, currently available experimental data regarding the cellular expression, localization and function of these ABCG2 variants are strongly contradictory. Since, the proteins produced by these variant alleles may differently modulate cancer treatment, general drug absorption and toxicity, may represent risk factors in fetal toxicity, or alter the differentiation of stem cells, their exact characterization is a major challenge in this field.

KW - ABC transporter proteins

KW - ABCG2

KW - Cancer drug resistance

KW - Multidrug transporter

KW - Plymorphic variants

KW - Xenobiotics resistance

UR - http://www.scopus.com/inward/record.url?scp=33644811431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644811431&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2005.01.061

DO - 10.1016/j.canlet.2005.01.061

M3 - Article

C2 - 16337740

AN - SCOPUS:33644811431

VL - 234

SP - 62

EP - 72

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -